CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Sensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs.
Sensitive detection of synthetic response to cancer immunotherapy driven by gene paralog pairs.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫检查点阻断和CAR-T 细胞疗法等免疫治疗改变了癌症治疗,但许多患者仍对治疗无应答或治疗后复发。CRISPR 筛选已用于识别可增强免疫治疗疗效的新型单基因靶点,但组合靶点的识别仍具挑战。本文介绍一种计算方法,利用 sgRNA 集合富集分析从全基因组筛选中识别癌细胞内在的旁系同源基因对,以增强免疫治疗。研究者进一步开发集成学习模型,使用 XGBoost 分类器并纳入多种特征,预测可影响免疫治疗疗效的旁系同源基因对。随后通过 CRISPR 双敲除(DKO)实验验证预测基因对的功能意义。这些数据和分析共同提供了一种高灵敏方法,可识别此前未发现的旁系同源基因对;即使基因对中的单个基因单独作用有限,这些基因对也可能显著影响癌症免疫治疗应答。
Immunotherapies, including checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy, have revolutionized cancer treatment; however, many patients remain unresponsive to these treatments or relapse following treatment. CRISPR screenings have been used to identify novel single gene targets that can enhance immunotherapy effectiveness, but the identification of combinational targets remains a challenge.
Here, we introduce a computational approach that uses sgRNA set enrichment analysis to identify cancer-intrinsic paralog pairs for enhancing immunotherapy using genome-wide screens.
We have further developed an ensemble learning model that uses an XGBoost classifier and incorporates features to predict paralog gene pairs that influence immunotherapy efficacy.
We experimentally validated the functional significance of these predicted paralog pairs using CRISPR double knockout (DKO). These data and analyses collectively provide a sensitive approach to identifying previously undetected paralog gene pairs that can significantly affect cancer immunotherapy response, even when individual genes within the pair have limited effect.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。